Best Biotech Stocks To Buy For 2015

Best Biotech Stocks To Buy For 2015: Exelixis Inc.(EXEL)

Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer. It focuses on developing Cabozantinib, an inhibitor of tumor growth, metastasis, and angiogenesis that target MET, VEGFR2, and RET, which are key kinases involved in the development and progression of various cancers. The cabozantinib is in Phase III clinical trial for the treatment for medullary thyroid cancer. The company also engages in various clinical programs for cabozantinib focused on the treatment of metastatic castration-resistant prostate cancer, ovarian cancer, breast cancer, renal cell carcinoma, non-small cell lung cancer, hepatocellular cancer, and melanoma. In addition, Exelixis, Inc. involves in developing a portfolio of other novel compounds to address serious unmet medical needs through collaborations with various pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, Genentech, Inc., Boehringer Ingelheim Gm bH, and GlaxoSmithKline and Daiichi Sankyo Company Limited. Its products under development through collaborations include XL475, XL281, XL139, and XL413 inhibitors; ROR antagonists; therapies targeted against LXR, a nuclear hormone receptor implicated in various cardiovascular and metabolic disorders; XL147, XL765, and isoform-selective PI3K inhibitors; XL518, a small-molecule inhibitor of MEK; sphingosine-1-phosphate type 1 receptor; XL880 inhibitor; and therapies targeted against the mineralocorticoid receptor, a nuclear hormone receptor implicated in various cardiovascular and metabolic diseases. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Advisors' Opinion:

• [By Dan Carroll]

  Around the market, however, three big losers didn't need Russia's help to take a beatin! g on the day. Biotech stock Exelixis (NASDAQ: EXEL  ) took the title of today's hardest-hit loser, plunging by a migraine-inducing 39.4%, while investors hammered fuel cell producer Plug Power (NASDAQ: PLUG  ) to the tune of a 24% drop. The most notable loser of the day, however, came from the market's newest stock, as shares of new IPO King Digital Entertainment (NYSE: KING  ) lit the market on fire in all the wrong ways today in its debut, plunging by 15.5%. Let's catch on up on the details.

• [By Roberto Pedone]

  Another under-$10 biotechnology player that's starting to trend within range of triggering a near-term breakout trade is Exelixis (EXEL), which develops small molecule therapies for the treatment of cancer in the U.S. This stock has been crushed by the bears so far in 2014, with shares down sharply by 41%.

  If you look at the chart for Exelixis, you'll notice that EXEL has been trending sideways and consolidating for the last two months and change, with shares moving between $3.02 on the downside and $3.84 on the upside. Shares of EXEL are starting to spike higher today right off its 50-day moving average of $3.42 a share. That spike is quickly pushing shares of EXEL within range of triggering a near-term breakout trade above some key overhead resistance levels.

  Market players should now look for long-biased trades in EXEL if it manages to break out above some near-term overhead resistance levels at $3.55 to $3.63 a share and then once it clears more resistance at $3.84 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 4.85 million shares. If that breakout kicks off soon, then EXEL will set up to re-test or possibly take out its next major overhead resistance level at its March gap-down-day high of $4.50 a share. Any high-volume move above $4.50 will then give EXEL a chance to re-fill some of its previous gap-down-day zone! that sta! rted at $6.66 a share.

  Traders can look to buy EXEL off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.18 to $3.02 a share. One can also buy EXEL off strength once it starts to move above those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/best-biotech-stocks-to-buy-for-2015-2.html